 Paul Christine
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 13 | 2025 | 568 | 3.630 |
Why?
| | Opiate Substitution Treatment | 8 | 2025 | 170 | 2.850 |
Why?
| | Buprenorphine | 6 | 2025 | 181 | 1.960 |
Why?
| | Methadone | 4 | 2025 | 108 | 1.280 |
Why?
| | Residence Characteristics | 4 | 2018 | 367 | 1.270 |
Why?
| | Narcotic Antagonists | 4 | 2025 | 193 | 1.150 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 2 | 2025 | 11 | 1.070 |
Why?
| | Analgesics, Opioid | 9 | 2025 | 1117 | 1.010 |
Why?
| | Naltrexone | 2 | 2025 | 101 | 0.990 |
Why?
| | Substance Withdrawal Syndrome | 6 | 2025 | 181 | 0.950 |
Why?
| | Environment Design | 2 | 2015 | 26 | 0.930 |
Why?
| | Medicaid | 3 | 2024 | 450 | 0.910 |
Why?
| | Insurance Coverage | 2 | 2024 | 239 | 0.900 |
Why?
| | Fentanyl | 5 | 2025 | 123 | 0.880 |
Why?
| | Food Supply | 2 | 2015 | 90 | 0.870 |
Why?
| | Social Environment | 2 | 2015 | 294 | 0.820 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 163 | 0.770 |
Why?
| | Insurance, Health | 1 | 2024 | 296 | 0.720 |
Why?
| | Motor Activity | 2 | 2015 | 717 | 0.670 |
Why?
| | Substance-Related Disorders | 3 | 2024 | 1100 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2017 | 2529 | 0.540 |
Why?
| | Drug Overdose | 4 | 2026 | 359 | 0.530 |
Why?
| | Housing | 1 | 2016 | 146 | 0.470 |
Why?
| | Massachusetts | 3 | 2024 | 176 | 0.470 |
Why?
| | Social Class | 1 | 2017 | 269 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1336 | 0.450 |
Why?
| | Economic Development | 1 | 2014 | 2 | 0.440 |
Why?
| | Health Transition | 1 | 2014 | 8 | 0.440 |
Why?
| | Middle Aged | 22 | 2026 | 34658 | 0.420 |
Why?
| | Substance Abuse, Intravenous | 2 | 2026 | 123 | 0.410 |
Why?
| | Atherosclerosis | 1 | 2017 | 402 | 0.400 |
Why?
| | Blood Pressure | 3 | 2025 | 1740 | 0.370 |
Why?
| | Group Processes | 1 | 2012 | 65 | 0.360 |
Why?
| | Body Mass Index | 3 | 2018 | 2390 | 0.360 |
Why?
| | Social Identification | 1 | 2012 | 72 | 0.340 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5653 | 0.330 |
Why?
| | Male | 25 | 2026 | 70140 | 0.320 |
Why?
| | Humans | 36 | 2026 | 141284 | 0.310 |
Why?
| | Overweight | 1 | 2014 | 589 | 0.310 |
Why?
| | Female | 26 | 2026 | 75814 | 0.300 |
Why?
| | Adult | 18 | 2026 | 39319 | 0.300 |
Why?
| | Patient Participation | 1 | 2013 | 427 | 0.300 |
Why?
| | Education, Medical | 1 | 2012 | 271 | 0.290 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 717 | 0.290 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2929 | 0.290 |
Why?
| | Interrupted Time Series Analysis | 2 | 2025 | 72 | 0.270 |
Why?
| | Students, Medical | 1 | 2012 | 370 | 0.260 |
Why?
| | United States | 8 | 2025 | 15298 | 0.250 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1311 | 0.250 |
Why?
| | Delayed-Action Preparations | 2 | 2025 | 175 | 0.250 |
Why?
| | Smoking | 4 | 2018 | 1576 | 0.250 |
Why?
| | Blood Glucose | 1 | 2016 | 2286 | 0.250 |
Why?
| | Needle-Exchange Programs | 1 | 2026 | 11 | 0.240 |
Why?
| | Decision Making | 1 | 2013 | 949 | 0.230 |
Why?
| | Xylazine | 1 | 2025 | 14 | 0.230 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2025 | 24 | 0.230 |
Why?
| | Heroin | 1 | 2025 | 31 | 0.220 |
Why?
| | Heroin Dependence | 1 | 2025 | 33 | 0.220 |
Why?
| | Kentucky | 1 | 2024 | 39 | 0.220 |
Why?
| | Cohort Studies | 4 | 2025 | 5809 | 0.220 |
Why?
| | Mifepristone | 1 | 2024 | 63 | 0.220 |
Why?
| | Amphetamine-Related Disorders | 1 | 2024 | 45 | 0.210 |
Why?
| | Diazepam | 1 | 2024 | 35 | 0.210 |
Why?
| | Ohio | 1 | 2024 | 139 | 0.210 |
Why?
| | New York | 1 | 2024 | 128 | 0.210 |
Why?
| | Hospitals, Urban | 1 | 2024 | 137 | 0.210 |
Why?
| | Young Adult | 9 | 2025 | 13727 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 124 | 0.200 |
Why?
| | Colorado | 4 | 2026 | 4599 | 0.200 |
Why?
| | Benzodiazepines | 1 | 2024 | 162 | 0.200 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1268 | 0.190 |
Why?
| | Central Nervous System Stimulants | 1 | 2024 | 178 | 0.190 |
Why?
| | Naloxone | 1 | 2024 | 130 | 0.190 |
Why?
| | Abortion, Induced | 1 | 2024 | 106 | 0.180 |
Why?
| | Health Care Costs | 1 | 2026 | 417 | 0.180 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2024 | 237 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 451 | 0.170 |
Why?
| | Adolescent | 9 | 2025 | 22116 | 0.170 |
Why?
| | Obesity | 1 | 2014 | 3007 | 0.170 |
Why?
| | Endocarditis, Bacterial | 1 | 2021 | 46 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7948 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2025 | 539 | 0.160 |
Why?
| | Economic Recession | 1 | 2018 | 4 | 0.150 |
Why?
| | Aged | 7 | 2021 | 24836 | 0.150 |
Why?
| | Unemployment | 1 | 2018 | 43 | 0.140 |
Why?
| | Risk Factors | 3 | 2017 | 10490 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1105 | 0.130 |
Why?
| | Argentina | 2 | 2014 | 28 | 0.130 |
Why?
| | Prevalence | 3 | 2024 | 2795 | 0.120 |
Why?
| | Smoke-Free Policy | 1 | 2015 | 13 | 0.120 |
Why?
| | Patient Care Team | 1 | 2021 | 667 | 0.120 |
Why?
| | Geographic Information Systems | 1 | 2015 | 45 | 0.110 |
Why?
| | Public Opinion | 1 | 2015 | 60 | 0.110 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2016 | 106 | 0.110 |
Why?
| | Behavior | 1 | 2015 | 92 | 0.110 |
Why?
| | Pandemics | 1 | 2023 | 1655 | 0.110 |
Why?
| | Models, Psychological | 1 | 2016 | 312 | 0.110 |
Why?
| | China | 1 | 2015 | 220 | 0.110 |
Why?
| | Alcohol Drinking | 2 | 2018 | 834 | 0.110 |
Why?
| | Spatio-Temporal Analysis | 1 | 2014 | 37 | 0.110 |
Why?
| | Incidence | 2 | 2024 | 2809 | 0.100 |
Why?
| | Prospective Studies | 2 | 2017 | 7805 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1312 | 0.100 |
Why?
| | Amnion | 1 | 2013 | 28 | 0.100 |
Why?
| | HIV Infections | 2 | 2026 | 2981 | 0.100 |
Why?
| | Nutrition Surveys | 1 | 2014 | 280 | 0.100 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2012 | 11 | 0.100 |
Why?
| | Health Behavior | 1 | 2018 | 784 | 0.100 |
Why?
| | Smoking Cessation | 1 | 2016 | 431 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 81 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 756 | 0.090 |
Why?
| | Diffusion of Innovation | 1 | 2012 | 96 | 0.090 |
Why?
| | Premature Birth | 2 | 2013 | 363 | 0.090 |
Why?
| | Science | 1 | 2012 | 52 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 373 | 0.090 |
Why?
| | Hospitalization | 3 | 2026 | 2264 | 0.080 |
Why?
| | Physician's Role | 1 | 2012 | 218 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 337 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 2055 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 2013 | 579 | 0.070 |
Why?
| | DNA Methylation | 1 | 2013 | 643 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3522 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2091 | 0.060 |
Why?
| | Communication | 1 | 2013 | 941 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2026 | 150 | 0.060 |
Why?
| | Philadelphia | 1 | 2024 | 53 | 0.050 |
Why?
| | Hostility | 1 | 2024 | 15 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 168 | 0.050 |
Why?
| | Hepatitis C | 1 | 2026 | 250 | 0.050 |
Why?
| | Health Surveys | 1 | 2025 | 511 | 0.050 |
Why?
| | Health Policy | 1 | 2024 | 385 | 0.040 |
Why?
| | Heart Rate | 1 | 2025 | 835 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2025 | 868 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 337 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2024 | 802 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 688 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1610 | 0.040 |
Why?
| | Pregnancy | 2 | 2024 | 7035 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 16447 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 938 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2024 | 1030 | 0.030 |
Why?
| | Educational Status | 1 | 2018 | 463 | 0.030 |
Why?
| | Mexico | 1 | 2015 | 229 | 0.030 |
Why?
| | Lipids | 1 | 2018 | 686 | 0.030 |
Why?
| | Quality of Life | 1 | 2025 | 3024 | 0.020 |
Why?
| | Receptors, Oxytocin | 1 | 2013 | 21 | 0.020 |
Why?
| | Indians, South American | 1 | 2012 | 22 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2015 | 238 | 0.020 |
Why?
| | CpG Islands | 1 | 2013 | 164 | 0.020 |
Why?
| | Labor, Obstetric | 1 | 2013 | 66 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 197 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2013 | 108 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2210 | 0.020 |
Why?
| | Genetic Loci | 1 | 2013 | 275 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 209 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 397 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6270 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 757 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11216 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2018 | 1124 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 619 | 0.020 |
Why?
| | Gestational Age | 1 | 2013 | 952 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1490 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1244 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 661 | 0.020 |
Why?
| | Fetus | 1 | 2012 | 797 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1854 | 0.020 |
Why?
| | Exercise | 1 | 2018 | 2113 | 0.020 |
Why?
| | Placenta | 1 | 2013 | 764 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1761 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2122 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2366 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5948 | 0.010 |
Why?
|
|
Christine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|